Powder: -20°C for 3 years | In solvent: -80°C for 2 years
CHM-1 是细胞凋亡的诱导剂,通过激活 Cdc2 激酶活性在人肝细胞癌中显示出有效的抗肿瘤能力。 CHM-1 在体外和体内抑制微管蛋白聚合。
产品描述 | CHM-1 is an inducer of apoptosis, and displays potent antitumor ability in human hepatocellular carcinoma by activation of Cdc2 kinase activity. CHM-1 inhibits tubulin polymerization in vitro and in vivo. |
靶点活性 | Apoptosis:0.75 μM (HA22T) |
体外活性 | CHM-1 (0-10 μM; 24 hours) significantly increased the binding of cyclin B1 to Cdc2 and induced change in expressed and phosphorylated status of G2-M regulators in HA22T cells. CHM-1 (0-100μM; 24 hours) induced significant concentration-dependent growth inhibition in HA22T, Hep3B, and HepG2 cells, with the most potent effects observed in HA22T cells with an IC50 of 0.75 μM)[3]. |
体内活性 | In male severe combined immunodeficient mice, CHM-1 (10 mg/kg; i.p.) induced inhibition of HA22T tumor growth in a dose-dependent manner[3]. |
分子量 | 283.25 |
分子式 | C16H10FNO3 |
CAS No. | 154554-41-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
H2O: <7.08mg/ml
( < 1 mg/mL refers to the product slightly soluble or insoluble )
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
bottom
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CHM-1 154554-41-3 Apoptosis Cytoskeletal Signaling Others Microtubule Associated Inhibitor microtubule-destabilizing Cdc2 carcinoma CHM1 NSC-656158 Microtubule/Tubulin hepatocellular NSC656158 antitumor inhibit CHM 1 antimitotic NSC 656158 inhibitor